128 related articles for article (PubMed ID: 11453523)
1. An open-label acceptability study of Norditropin SimpleXx--a new liquid growth hormone formulation.
Stanhope R; Buchanan C; Butler G; Costigan C; Dunger D; Greene S; Hoey H; Hughes I; Kelnar C; Kirk J; Komulainen J; Lowry M; Warner J
J Pediatr Endocrinol Metab; 2001 Jun; 14(6):735-40. PubMed ID: 11453523
[TBL] [Abstract][Full Text] [Related]
2. Norditropin SimpleXx: a liquid human growth hormone formulation, a pen system and an auto-insertion device.
Müller J; Skakkebaek NE; Jacobsen BB; Keller E; Heinrich U; Hartmann K; Hokken-Koelega AC; Delemarre van de Waal HA
Horm Res; 1999; 51 Suppl 3():109-12. PubMed ID: 10592453
[TBL] [Abstract][Full Text] [Related]
3. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.
Fuchs GS; Mikkelsen S; Knudsen TK; Kappelgaard AM
Clin Ther; 2009 Dec; 31(12):2906-14. PubMed ID: 20110030
[TBL] [Abstract][Full Text] [Related]
4. The clinical usefulness of liquid human growth hormone (hGH) (Norditropin SimpleXx in the treatment of GH deficiency.
Iyoda K; Moriwake T; Seino Y; Niimi H
Horm Res; 1999; 51 Suppl 3():113-5. PubMed ID: 10592454
[TBL] [Abstract][Full Text] [Related]
5. Acceptability of Liquid Human Growth Hormone (hGH) [Norditropin Simple Xx®] in Adults and Children with GH Deficiency and Children with Chronic Renal Disease.
Drent ML; Jakobsdottir S; van Wijk JAE; Oostdijk W; Wit JM
Clin Drug Investig; 2002 Sep; 22(9):633-638. PubMed ID: 29492857
[TBL] [Abstract][Full Text] [Related]
6. Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients.
Kappelgaard AM; Mikkelsen S; Knudsen TK; Fuchs GS
J Pediatr Endocrinol Metab; 2011; 24(7-8):489-96. PubMed ID: 21932587
[TBL] [Abstract][Full Text] [Related]
7. Children and adolescent acceptability of a new device system to administer human growth hormone--a pilot study.
Kappelgaard AM; Mikkelsen S; Bagger C; Fuchs GS
J Pediatr Endocrinol Metab; 2012; 25(3-4):285-94. PubMed ID: 22768658
[TBL] [Abstract][Full Text] [Related]
8. Liquid growth hormone: preservatives and buffers.
Kappelgaard AM; Bojesen A; Skydsgaard K; Sjögren I; Laursen T
Horm Res; 2004; 62 Suppl 3():98-103. PubMed ID: 15539807
[TBL] [Abstract][Full Text] [Related]
9. Assessment of user-friendliness of the Norditropin FlexPro for pediatric patients treated with recombinant human growth hormone: results of an open-label user survey.
Adachi M
J Pediatr Endocrinol Metab; 2013; 26(11-12):1105-10. PubMed ID: 23843576
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone therapy with norditropin ( somatropin ) in growth hormone deficiency.
Pawlikowska-Haddal A
Expert Opin Biol Ther; 2013 Jun; 13(6):927-32. PubMed ID: 23662811
[TBL] [Abstract][Full Text] [Related]
11. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
[TBL] [Abstract][Full Text] [Related]
12. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial.
Johannsson G; Feldt-Rasmussen U; Håkonsson IH; Biering H; Rodien P; Tahara S; Toogood A; Rasmussen MH;
Eur J Endocrinol; 2018 May; 178(5):491-499. PubMed ID: 29500310
[TBL] [Abstract][Full Text] [Related]
13. [Growth hormone (GH) deficiency treatment in children: comparison between uses of pen versus bottles/syringes on GH administration].
Marchisotti FG; Carvalho LR; Berger K; Arnhold IJ; Mendonça BB
Arq Bras Endocrinol Metabol; 2007 Oct; 51(7):1093-6. PubMed ID: 18157384
[TBL] [Abstract][Full Text] [Related]
14. Optimum method for administration of biosynthetic human growth hormone: a randomised crossover trial of an Auto Injector and a pen injection system.
Stanhope R; Albanese A; Moyle L; Hamill G
Arch Dis Child; 1992 Aug; 67(8):994-7. PubMed ID: 1520018
[TBL] [Abstract][Full Text] [Related]
15. Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis.
Pollock RF; Qian Y; Wisniewski T; Seitz L; Kappelgaard AM
Med Devices (Auckl); 2013; 6():107-14. PubMed ID: 23946672
[TBL] [Abstract][Full Text] [Related]
16. Comparison of intuitiveness, ease of use and preference among three prefilled, disposable growth hormone injection pens.
Rohrer TR; Winter F; Qvist M; Kappelgaard AM
Expert Opin Drug Deliv; 2013 Dec; 10(12):1603-12. PubMed ID: 24073645
[TBL] [Abstract][Full Text] [Related]
17. Psychological responses to the needle-free Medi-Jector or the multidose Disetronic injection pen in human growth hormone therapy.
Verrips GH; Hirasing RA; Fekkes M; Vogels T; Verloove-Vanhorick SP; Delemarre-Van de Waal HA
Acta Paediatr; 1998 Feb; 87(2):154-8. PubMed ID: 9512200
[TBL] [Abstract][Full Text] [Related]
18. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
Whitman BY; Myers S; Carrel A; Allen D
Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone therapy with a new delivery system.
Jørgensen JT; Susgaard S
Indian J Pediatr; 1991; 58 Suppl 1():43-50. PubMed ID: 1824374
[TBL] [Abstract][Full Text] [Related]
20. User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study.
Tauber M; Jaquet D; Jesuran-Perelroizen M; Petrus M; Bertrand AM; Coutant R;
Patient Prefer Adherence; 2013; 7():455-62. PubMed ID: 23737664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]